BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026)
BiomX (PHGE) posted Total Non-Current Liabilities of $1.7 million for Q1 2026, up 138.67% sequentially from $706000.0 in Q4 2025, and down 88.08% YoY from $14.1 million in Q1 2025.
BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
BiomX has reported Total Non-Current Liabilities for 9 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 88.08% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 88.08% YoY) and the FY2025 annual result came in at $706000.0, down 93.47% from the prior year.
- Total Non-Current Liabilities grew to $1.7 million in Q1 2026 per PHGE's latest filing, from $706000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $33.9 million in Q2 2024 and troughed at $706000.0 in Q4 2025.
- A 5-year average of $13.8 million and a median of $13.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 261.51% in 2022, then sank 93.47% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $16.6 million in 2022, then sank by 34.92% to $10.8 million in 2023, then gained by 0.43% to $10.8 million in 2024, then tumbled by 93.47% to $706000.0 in 2025, then jumped by 138.67% to $1.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.7 million, $706000.0, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 10.46 Mn |
| Jun 30, 2025 | 12.63 Mn |
| Mar 31, 2025 | 14.13 Mn |
| Dec 31, 2024 | 10.82 Mn |
| Sep 30, 2024 | 13.14 Mn |
| Jun 30, 2024 | 33.89 Mn |
| Dec 31, 2023 | 10.77 Mn |
| Sep 30, 2023 | 12.12 Mn |
| Jun 30, 2023 | 13.72 Mn |
| Mar 31, 2023 | 15.06 Mn |
| Dec 31, 2022 | 16.55 Mn |
| Sep 30, 2022 | 17.86 Mn |
| Jun 30, 2022 | 19.15 Mn |
| Mar 31, 2022 | 18.88 Mn |
| Dec 31, 2021 | 19.41 Mn |
| Sep 30, 2021 | 19.37 Mn |
| Jun 30, 2021 | 5.30 Mn |
| Mar 31, 2021 | 5.31 Mn |